share_log
  • Headlines
  • Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'

Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'

Benzinga ·  Dec 17 20:36
Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated